| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Stephen W Webster is Director at VKTX. Stephen W Webster's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $209K at current prices.
Net of sales, the VKTX filings show accumulation of 8,000 shares.
Stephen W Webster has 22 Form 4 filings on record from April 2015 to June 2026, across 4 companies: Director at NextCure (NXTC), 2019–2026; Director at Cullinan Therapeutics (CGEM), 2021–2026; Director at Eloxx Pharmaceuticals (ELOX), 2026, and 1 more.
The 22 reported transactions were 21 option or other derivative awards and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $42K and no sales.
The only open-market purchase was 8,000 shares of VKTX at an average $5.21 on May 29, 2018, about $42K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 29, 2018 | VKTX Viking Therapeutics, Inc. | Director | Buy | 8,000 | $5.21 | $41,712.00 | New |